A Phase 2 interventional study of Venlafaxine ER and Sugar pill in Anxiety Disorders, sponsored by National Center for Complementary and Integrative Health (NCCIH). Terminated. Per ClinicalTrials.gov, last updated 2012-10-19.
Sponsored by National Center for Complementary and Integrative Health (NCCIH) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the safety and effectiveness of the herbal medicine kava kava for the treatment of generalized anxiety disorder (GAD).
Kava kava (KAV) is a plant-derived treatment widely used in Europe to treat anxiety disorders. Several studies suggest that KAV may be effective in reducing anxiety symptoms; however, trial data are limited. This study will compare KAV, the drug venlafaxine-XR (VEN), and placebo for the treatment of GAD.
This study will last 10 weeks. Participants will be randomly assigned to receive KAV, VEN, or placebo for 8 weeks. Participants will then undergo a 1-week tapering of their medication followed by an additional week of observation. Self-report scales and questionnaires will be used to assess the anxiety, depression, and functional impairment of participants. Side effects, vital signs, and laboratory measures will be monitored throughout the study.
7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.
This study's enrollment of 16 is below the median of 80 across 6,103 interventional studies indexed under Anxiety Disorders.
Browse Anxiety Disorders studies →National Center for Complementary and Integrative Health (NCCIH) is the lead sponsor of 223 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Venlafaxine ER
Drug: Venlafaxine ER · Drug: Sugar pill
Inert placebo pills as duble dummy - up to 4 per day for kava and 3 per day for venlafaxine
Drug: Sugar pill
Kava
Drug: Sugar pill · Drug: Kava
75 to 225 mg daily
Also known as: Effexor XR
Upto 3 per day for venlafainxe and 4 per day for kava placebos.
Also known as: No brand name
140 to 280 mg per day
Also known as: No brand name
Hamilton Anxiety Scale
Time frame: 8 weeks
No study locations are listed for this record.
The record gives a start of Jun 2002, a primary completion of Jun 2004 and a completion of Aug 2004. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Piper methysticum root
National Center for Complementary and Integrative Health (NCCIH) →